Tim is the Chairman & CEO of GPN Vaccines. He has extensive expertise in the life sciences, executive management and venture capital investment. Tim was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund, the Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. He is an active angel investor working with investment groups throughout Australia and US to assist early stage companies to raise capital and develop their innovative technologies. Tim is also Chairman of Gamma Vaccines Pty Ltd, Chairman of Brain Changer Pty Ltd, Director of Emudent Technologies Pty Ltd, Director of Flex-G Pty Ltd, Trustee Director of Griffin Accelerator Holdings Pty Ltd and an Honorary Adjunct Professor at the University of Adelaide.
Mohammed is a director of GPN Vaccines as well as a Senior Lecturer in Virology & Immunology at The University of Adelaide and Chief Scientific Officer of Gamma Vaccines Pty Ltd. Mohammed brings a wealth of experience in the use of gamma-irradiation to inactivate viral and bacterial pathogens and he was a Chief Investigator on the ARC Linkage grant that led to the development of the Gamma-PN vaccine program and the NHMRC Development Grant that is supporting its final preclinical development.
Martin is a director of GPN Vaccines as well as the General Manager of Capricorn Consilium GmbH (Ltd.) – a Vienna–based consulting and interim management company. Martin has extensive experience in the vaccine pharma-industry with over 20 years at Behringwerke AG/Chiron Vaccines International, including as Global Head of Production and Sales Logistics and as Director Commercial Operations. He was also VP Marketing, Sales & Supply at Intercell AG (today Valneva), a company focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases.
Barry is a director of GPN Vaccines as well as the CEO of Aionious, a Social Impact Investment group headquartered in Sydney and Hong Kong. He is the Emeritus Chairman of the International Association of Investment Bankers (www.iaib.org). During his Chairmanship, he expanded IAIB’s coverage into China, Japan, Brazil, Italy and France. Barry is also Founding Partner of the Aionious Healthcare Fund which is focused on commercialising world leading healthcare technologies. Barry has extensive experience in commercialising disruptive technologies in Australia, US, UK & China and has also served as the start-up CEO of a globally successful high technology company. His prior corporate career included Head of Mergers, Acquisitions and Strategic Development for the funds management business of Australia’s largest Bank, CBA. Barry is a professionally qualified actuary.
James is a director of GPN Vaccines as well as Professor of Microbiology and the Director of the Research Centre for Infectious Diseases at the University of Adelaide. He is Australia’s preeminent authority on the pathogenesis of S. pneumoniae and recently was South Australian Scientist of the Year (2017). James is a former NHMRC Australia Fellow and Senior Principle Research Fellow and he directs an internationally acclaimed team of researchers at the University of Adelaide. He has published over 370 research papers and in the last 8 years has raised over $36M in grants to support his research activities. James was the lead Chief Investigator on the ARC Linkage grant that led to the development of the Gamma-PN vaccine and the NHMRC Development Grant that is supporting its final preclinical development.